QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Forecast, Price & News

$9.89
-0.13 (-1.30%)
(As of 06/7/2023 ET)
Compare
Today's Range
$9.81
$10.34
50-Day Range
$5.71
$10.12
52-Week Range
$5.53
$14.33
Volume
137,646 shs
Average Volume
169,187 shs
Market Capitalization
$625.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Edgewise Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
71.9% Upside
$17.00 Price Target
Short Interest
Bearish
11.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.10mentions of Edgewise Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$101,789 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.66) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

907th out of 981 stocks

Pharmaceutical Preparations Industry

432nd out of 464 stocks


EWTX stock logo

About Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Stock News Headlines

Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 5.6%
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
RBC Capital Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)
See More Headlines

EWTX Price History

EWTX Company Calendar

Last Earnings
11/10/2021
Today
6/07/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+71.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-67,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
43,061,000
Market Cap
$625.84 million
Optionable
Not Optionable
Beta
-0.13

Key Executives

  • Dr. Kevin Koch Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $845.33k
  • Dr. Badreddin Edris Ph.D. (Age 36)
    Co-Founder & Independent Director
    Comp: $36.26k
  • Dr. Behrad Derakhshan Ph.D. (Age 43)
    Chief Bus. Officer
    Comp: $575.53k
  • Dr. Joanne M. Donovan M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $556.23k
  • Dr. Alan J. Russell Ph.D. (Age 53)
    Co-Founder, Chief Scientific Officer & Director
  • Mr. R. Michael Carruthers (Age 65)
    Chief Financial Officer
  • Mr. John R. Moore (Age 59)
    Gen. Counsel
  • Dr. Marc Semigran M.D. (Age 66)
    Chief Devel. Officer













EWTX Stock - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EWTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EWTX, but not buy additional shares or sell existing shares.
View EWTX analyst ratings
or view top-rated stocks.

What is Edgewise Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 12-month price targets for Edgewise Therapeutics' shares. Their EWTX share price forecasts range from $5.00 to $29.00. On average, they anticipate the company's share price to reach $17.00 in the next year. This suggests a possible upside of 71.9% from the stock's current price.
View analysts price targets for EWTX
or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2023?

Edgewise Therapeutics' stock was trading at $8.94 at the beginning of the year. Since then, EWTX stock has increased by 10.6% and is now trading at $9.89.
View the best growth stocks for 2023 here
.

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our EWTX earnings forecast
.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its earnings results on Wednesday, November, 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05.

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

What is Edgewise Therapeutics' stock symbol?

Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX."

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (12.55%), BlackRock Inc. (4.54%), Geode Capital Management LLC (1.23%), Granahan Investment Management LLC (1.16%), State Street Corp (1.04%) and American Century Companies Inc. (0.80%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends
.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edgewise Therapeutics' stock price today?

One share of EWTX stock can currently be purchased for approximately $9.89.

How much money does Edgewise Therapeutics make?

Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $625.84 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How can I contact Edgewise Therapeutics?

Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com.

This page (NASDAQ:EWTX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -